West Pharma (WST) Tops Q2 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Dow, S&P 500 fall, tech steadies to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude jumps to highest since April on Houthi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts WST Hot Sheet
Price: $389.73 -1.09%
Revenue Growth %: +2.8%
Financial Fact:
Gross profit: 121.1M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Revenue Growth %: +2.8%
Financial Fact:
Gross profit: 121.1M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
West Pharmaceutical Services, Inc. (NYSE: WST) reported Q2 EPS of $0.52, $0.05 better than the analyst estimate of $0.47. Revenue for the quarter came in at $368.9 million versus the consensus estimate of $368.6 million.
West Pharmaceutical Services, Inc. reaffirmed FY2014 guidance.
For earnings history and earnings-related data on West Pharmaceutical Services, Inc. (WST) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AI-powered cyber threats light a fire under cybersecurity stocks
- Bristol Myers Squibb MS CAR T therapy data shows patients off DMTs
- Booz Allen Hamilton falls despite earnings beat
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
